• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bayer submits NDA for radium Ra 223 dichloride for castration-resistant prostate cancer

Bayer submits NDA for radium Ra 223 dichloride for castration-resistant prostate cancer

December 14, 2012
CenterWatch Staff

Bayer HealthCare has submitted a New Drug Application (NDA) to the FDA seeking approval for radium Ra 223 dichloride (radium-223), a fast tracked investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

Radium Ra 223 is an alpha particle emitting pharmaceutical and was granted Fast Track designation by the FDA.

“If approved, radium-223 has the potential to play a key role in the treatment of men with CRPC that has metastasized to the bone,” said Pamela A. Cyrus, MD, vice president and head of U.S. medical affairs, Bayer HealthCare Pharmaceuticals. “The development of a compound like radium-223 is an example of Bayer’s commitment to investing in approaches to treat hard-to-treat cancers.”

The submission was based on data from the ALSYMPCA trial, a phase III, randomized, double-blind, placebo-controlled international study of radium-223 with BSC versus placebo with BSC in symptomatic CRPC patients with bone metastases. The trial enrolled 921 patients in more than 100 centers in 19 countries. The study treatment consisted of up to six intravenous administrations of radium-223 or placebo each separated by an interval of four weeks.

The primary endpoint of the study was overall survival. Secondary endpoints included time to occurrence of skeletal-related events (SRE), time to total alkaline phosphatase (ALP) and prostate-specific antigen (PSA) progression, total ALP response and normalization, safety, and quality of life.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing